A private investment firm based in West Coast USA invests across all stages, from company formation through IPO. As an evergreen fund, the firm has invested in big name biotech companies, and is capable of making large investments with no set limit.
The firm is primarily focused on 3 areas: (1) therapeutics, (2) diagnostics, and (3) synthetic biology, but open to other sectors with groundbreaking technology.
The firm has a flexible mandate and does not have any specific company or management team requirements.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
Hot Investor Mandate: Private Investment Firm Seeks Opportunities in Therapeutics, Diagnostics, Synthetic Biology, and Other Groundbreaking Technology
17 Feb- Comments Leave a Comment
- Categories Hot Mandates
Popular Topics
Listen to the Podcast
Top Posts
- Hot Investor Mandate: Funding Arm of USA-Based Health System Invests in Digital Health Solutions With Strong Strategic Alignment
- Hot Investor Mandate: Multi-Billion AUM Investment Firm Seeks to Invest in All Areas of Life Sciences & Healthcare Across the Globe
- 11 Tips for Creating a Successful Pitch Deck
- RESI Boston Panels
- Hot Investor Mandate: VC With US & Europe Offices Seeks Early-Stage Life Science Companies in All Sectors, With Strong Interest in Platform Technologies
- Hot AI Mandate: USA-based Corporate Venture Capital with Flexible Check Size Interested in Digital Health and Diagnostics
- First Loss Capital - What, Why & How?
- Congratulations to Digital RESI September Innovator’s Pitch Challenge Winners!
- Companies to Watch in 2022
- Hot AI Mandate: California and Israel Based VC Interested in Therapeutics and Diagnostics/R&D Tools
Recent Posts
- Congratulations to the IPC Winners, Next Up RESI Boston, June 5-7
- Digital RESI March – A Tailor Made Conference for Early-Stage Life Science Fundraising Startups
- Audience Access Pass – A Runway for Your Fundraising Journey
- Innovator’s Pitch Challenge Judges at Digital RESI March
- Hot Investor Mandate: Multi-Billion AUM Investment Firm Seeks to Invest in All Areas of Life Sciences & Healthcare Across the Globe
Hot Mandates
-
Hot Investor Mandate 1: Korean VC Firm with Pharma Affiliation Seeks to Invest in Early Stage Therapeutics Assets, Most Interested in Oncology and Autoimmune Disease
The firm is focused on therapeutics companies and does not invest in medical devices, diagnostics, or digital health. The firm is open to considering assets of very early stages, even those as early as lead optimization phase. The firm considers various modalities, including antibodies, small molecules, and cell therapy. Currently, the firm is not interested in gene therapy. Indication-wise, the firm is most interested in oncology and autoimmune diseases but has recently looked at fibrotic diseases and certain rare diseases as well.
-
Hot Investor Mandate 2: Hong Kong Boutique VC Firm Invests in All Kinds of Healthcare Technologies and Most Interested in Large Disease Markets of Unmet Medical Need
The firm is opportunistic across all subsectors of healthcare. Within MedTech, the firm is most interested in medical devices, artificial intelligence, robotics, and mobile health. The firm is seeking post-prototype innovations that are FDA cleared or are close to receiving clearance. Within therapeutics, the firm is interested in therapeutics for large disease markets such as oncology, neurology, and metabolic diseases. The firm is open to all modalities with a special interest in immunotherapy and cell therapy.
-
Hot Investor Mandate 3: Strategic Investment Firm of Large Pharma Invests in Early and Late Stage Therapeutics & Drug-Device Combinations, Especially Interested in Orphan and Rare Diseases
A strategic investment firm of a large global pharmaceutical makes investments ranging from $5 million to $30 million, acting either as a sole investor or within a syndicate. The firm is open to considering therapeutic opportunities globally, but only if the company is pursuing a market opportunity in the USA and is in dialogue with the US FDA.
-
Hot Investor Mandate 4: USA-Based Investment Firm Can Invest Over $10M in Innovative Medtech and Digital Health Companies Based in Texas or Southwestern USA
The firm is currently looking for new investment opportunities in enterprise software, medical devices, and the healthcare IT space. The firm will invest in 510k devices and healthcare IT companies, and it is very opportunistic in terms of indications. In the past, the firm was active in medical device companies developing dental devices, endovascular innovation devices, and women’s health devices.
-
Hot Investor Mandate 1: Global VC Firm Headquartered in Asia Invests in All Parts of Therapeutics, Medical Devices, Diagnostics, and Digital Health
A venture capital firm founded in 2005 has multiple offices throughout Asia, New York, and San Diego. The firm has closed its fifth fund in 2017 and is currently raising a sixth fund, which the firm is targeting to be the largest fund to date. The firm continues to actively seek investment opportunities across a […]
LSN Twitter
- RT @UMassM2D2: In two week,s @LSciNation is awarding a 2-day virtual registration to the upcoming RESI Boston to one #Startup in the Cycle… 4 days ago
- Tech Hub Monthly! A newsletter for tech hub staff who are looking to increase #fundraising and marketing efforts fo… twitter.com/i/web/status/1… 5 days ago
- Congratulations to the three Innovator's Pitch Challenge (IPC) winners - SiVEC Biotechnologies, Reglagene &… twitter.com/i/web/status/1… 5 days ago
- Congratulations to Digital RESI March IPC Winners – SiVEC Biotechnologies, Reglagene & @AmpSciences! Now accepting… twitter.com/i/web/status/1… 1 week ago
- RESI is coming back to Boston this June as a hybrid format with a one-day (June 5) in-person conference experience… twitter.com/i/web/status/1… 1 week ago
- RT @ditcaldwell: Enjoyed pitching alongside @theradaptive and @kortuc_inc in the Digital #RESI #Innovators Pitch Challenge yesterday. #star… 1 week ago
Leave a Reply